BSE filing, NSE: SUNPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,769.90
- Market cap
- ₹4,24,658 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 38.7×Sector 47.2×
- Promoter holding
- 52.68%-1.80% QoQ
- FII holding
- 14.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Price Movement Clarification
Sun Pharma said a 30 October 2026 news report concerned August 2026 developments, not new events. It confirmed no undisclosed material information explains the share price movement.
Sun Pharmaceutical Industries Annual General Meeting
Sun Pharma's postal ballot passed all seven special resolutions, including ESOP 2026 approval and borrowing and security limits. No monetary transaction is stated.
Sun Pharmaceutical Industries Earnings Call Transcript: Key Takeaways
Sun Pharma delivered resilient double-digit revenue growth despite U.S. specialty headwinds, masking underlying margin pressure from lower Lenalidomide sales.
Sun Pharmaceutical Industries Other Announcement
Sun Pharma's board appointed Deloitte as Statutory Auditors under mandatory rotation, effective from the FY 2026-27 AGM. This follows SRBC & CO's second five-year term completion.
Sun Pharmaceutical Industries Q2 FY27 Results: Net Profit ₹1,995 Cr, Down 36.2% YoY
Sun Pharmaceutical Industries Ltd reported revenue from operations of ₹16,199 Cr (+11.9% YoY) and net profit of ₹1,995 Cr (-36.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,995 Cr · -36.2% YoY
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
Other merger & restructuring announcements
All →Jupiter Wagons Merger & Restructuring
Jupiter Wagons incorporated a 99% subsidiary, Jupiter Green Power Solutions Private Limited, on 3 November 2026. The subsidiary is in the energy and power sector and has not yet started operations.
Dalmia Bharat Sugar and Industries Merger & Restructuring
Dalmia Bharat Sugar will absorb Hippostores' agri-tech undertaking via redeemable preference shares, with no cash paid. Listed equity shareholding stays unchanged; the preference shares will not be listed.
GSPL Transmission Merger & Restructuring Worth ₹1.78 Cr
GSPL Transmission distributed Rs 1.78 Crore of fractional-share sale proceeds and dividend to eligible shareholders under the scheme. Independent Directors certified compliance with SEBI norms.
- Value
- ₹1.78 Cr
SC Agrotech Merger & Restructuring
SC Agrotech incorporated a wholly owned subsidiary, SC Careoasis Healthcare Private Limited, on 30 October 2026. It operates in the pharma sector, with 100% initial shareholding.
Shubhlaxmi Jewel Art Merger & Restructuring
Shubhlaxmi Jewel Art's board proposed approval to sell its whole undertaking and raise borrowing powers to Rs.500 Crore. An EGM is set for December 1, 2026.
Capital Trade Links Merger & Restructuring Worth ₹0.01 Cr
Capital Trade Links incorporated wholly owned subsidiary Rentworks Services India Private Limited for renting and leasing. It subscribed 10,000 shares for Rs 1 lakh cash.
- Value
- ₹0.01 Cr